Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
EYPT.US
id: 2384

EyePoint (EYPT) Misleading DURAVYU Clinical Trial Expectations and Failed Phase 3 Studies Case

Attorneys review the case details to decide whether to proceed with a class action.
E.D. New York
Court
1:26-cv-07418
Case number
05/27/2025
Class period Start
08/14/2026
Class period End
01/18/2027
Lead Plaintiff motion deadline
  • $EYPT investors filed a claim against EyePoint for allegedly overstating the effectiveness of DURAVYU, its experimental treatment for wet age-related macular degeneration (wet AMD), while misleading investors about the drug's chances of clinical success, regulatory approval, and commercial potential.

  • On August 17, 2026, EyePoint announced that its Phase 3 LUGANO clinical trial failed to meet its primary goal of preserving patients' vision. Following the announcement, $EYPT fell 66.98%,. On October 19, 2026, the Company disclosed that its second Phase 3 trial, LUCIA, had also failed, sending the stock down another 85.28%.

  • $EYPT investors can join this case to be notified about potential recovery.

Case Details:

EyePoint develops treatments for serious eye diseases using technology designed to release medication over extended periods. Its leading drug candidate, DURAVYU, was being developed to treat wet AMD, a condition that can cause severe vision loss. The Company was testing DURAVYU in two Phase 3 clinical trials, LUGANO and LUCIA, to determine whether it could preserve patients' vision as effectively as an existing treatment while reducing the need for frequent injections.

Throughout 2025, EyePoint promoted DURAVYU as a promising treatment supported by positive results from earlier Phase 2 studies. Management repeatedly highlighted the drug's effectiveness, long-lasting benefits, and potential to become a leading treatment for wet AMD.

On May 27, 2025, EyePoint announced that it had completed patient enrollment in the LUGANO trial. On July 29, the Company reported completing enrollment in LUCIA. Executives emphasized that favorable earlier clinical results supported the likelihood of success in both studies.

On March 4, 2026, EyePoint again expressed confidence in DURAVYU, describing its Phase 3 development program as having reduced clinical risk and suggesting that the drug was well positioned for regulatory approval. Management continued promoting its effectiveness and commercial potential in May and August 2026.

On August 17, 2026, EyePoint announced that the LUGANO trial had failed to meet its primary endpoint, which measured changes in patients' vision compared with an existing treatment. Management attributed the disappointing results to an unusual imbalance between patient groups and suggested that the problem was unlikely to occur in the LUCIA trial.

Following the announcement, $EYPT shares plunged 66.98%, falling $9.88 to close at $4.87 per share.

On October 19, 2026, EyePoint disclosed that the LUCIA trial had also failed to meet its primary efficacy goal. The Company announced that it would discontinue its late-stage wet AMD clinical program and reduce its workforce by 53%. Following these disclosures, the stock declined another 85.28%, closing at $0.44 per share.

Based on these events, $EYPT investors filed a claim against EyePoint, alleging the Company:

  • Overstated the effectiveness of DURAVYU and its ability to preserve vision in patients with wet AMD.

  • Misled investors about the likelihood of success in its Phase 3 LUGANO and LUCIA clinical trials by relying on favorable results from earlier studies.

  • Exaggerated DURAVYU's potential for regulatory approval and commercial success despite uncertainties surrounding its clinical effectiveness.

Investors argue that had the truth about DURAVYU's effectiveness, clinical development risks, and uncertain commercial prospects been disclosed, EyePoint securities would not have traded at artificially inflated prices during the Class Period of May 27, 2025, through August 14, 2026.

Case Type
US Securities Class Action
Case Status
Attorney Investigation
Alleged Offence
Misleading Statements, 
Fraud, 
Failure to Disclose, 
Omissions
Suspected Party
Directors, 
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
08/17/2026
Filing date
11/17/2026
Lead Plaintiff Deadline
01/18/2027